Sunday, September 27, 2020

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Million Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 43.1% YoY to RMB942...

WuXi AppTec: Collaborating Against COVID-19

WuXi AppTec is convening and working together with experts, from our company and around the world, for ongoing analysis of the COVID-19 pandemic. We are also partnering with other industry leaders on actions to address it. As we continue to collaborate with...

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and...

WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform

World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients May 18, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing...

WuXi AppTec Reports Solid First-Quarter 2020 Results

Revenue Up 15.1% Year-Over-Year to RMB3,188 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 10.8% Year-Over-Year to RMB576 Million Adjusted Diluted Non-IFRS EPS Up 9.4% Year-Over-Year to RMB0.351  (SHANGHAI,...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS